UCLouvain
" To confirm endothelial dysfunction in severe covid-19 patients admitted in Intensive Care Unit "
Funding: actually private; but waiting answer for credit urgent de recherche by FNRS
Publication References: 1) Manoury B, Montiel V, Balligand JL (2012). Nitric oxide synthase in post-ischaemic remodelling: New pathways and mechanisms. Cardiovascular Research, 94(2), 304-315. 2) Montiel V, Leon Gomez E, Bouzin C, Esfahani H, Romero Perez M, Lobysheva I, Balligand JL (2014). Genetic deletion of aquaporin-1 results in microcardia and low blood pressure in mouse with intact nitric oxide-dependent relaxation, but enhanced prostanoids-dependent relaxation. Pflugers Archiv European Journal of Physiology, 466(2), 237-251. 3) Montiel V, Robinson E, Bella R, Michel L, Esfahani H, De Mulder D, Deglasse JP, Jonas JC, Steinhorn B, Michel T, Beauloye C, Bertrand L, Farah C, Dei Zotti F, Bouzin C, Brusa D, Bergmann O, Gilis D, Rooman M, Roderick L, Devuyst O, Balligand JL. Cardiac...

Read more: Virginie Montiel, Professor

USL-B 
" The pharmaceutical industry is confronted with many different issues at the levels of logistics and supply chain management. Traceability is a paramount in the pharmaceutical sector. It is not only essential to ensure the quality of the product, but also, it is required to trace possible adverse reactions back to a given lot of drug product, its manufacturing and control. Traceability needs to be addressed at three stages. First, the source (supplier) and origin (e.g. chemical, microbiological, animal, human…) of raw and starting materials must be identified. These materials must be tested and found compliant with compendial requirements. Second, traceability must be ensured in-house, throughout the all manufacturing process, from starting materials to the drug product, through the drug substance and all intermediates. Third, traceability should be ensured downstream, from lot release by the company to patient's administration. Traceability within the industry (stage 2) is...

Read more: Wim Laurier, Chargé de cours

ULiège - Royal Academy of Medicine of Belgium
" In the context of the COVID-19 pandemic, this project involves collecting samples of human bodily material (HBM) for research projects aimed at better understanding and fighting this disease. 1 / Collection of blood and respiratory HBM from 500 patients with COVID-19 virus infection, as well as of post-mortem kidney and lung biopsies. 2 / Collection of blood HBM from 4000 healthy hospital and university staff members, currently not infected with the SARS-CoV2 virus, but possibly previously infected. SARS-CoV2 serology will be measured at 3 time points during the pandemia. "
Funding: Fondation Léon Frédéricq Wallonia Region ULiège CHU Liège
Contact: Pascale Huynen, Dpt of Microbiology, CHU of Liège. Stéphanie Gofflot, BHUL (CHU of Liège biobank).

Uliège & CHU of Liège - Royal Academy of Medicine of Belgium
" This is a phase 1-2 clinical trial entitled "Mesenchymal stromal cell therapy for severe COVID-19 infection" exploring the safety and preliminary efficacy of treatment with mesenchymal stromal cells in patients with severe COVID-19 infection. "
Funding: CHU of Liège
Contact: Céline Grégoire, Dpt of Hematology M Moutschen, Dpt of Microbiology B Misset, Dpt of Intensive Care C Lechanteur, Lab of Cell Therapy CHU of Liège

ULiège and Centre Hospitalier Régional de la Citadelle (service de biologie clinique)
" Data have been collected by the clinical laboratory of the regional hospital on Covid-19 infected patients who needed hospitalisation in March-April 2020. Using these data collected on the day of admission, data mining techniques have been applied in order to determine whether it is possible to classify the patients into one out of two groups corresponding to a favorable or an unfavorable evolution. "
Contact: M. Schyns (This email address is being protected from spambots. You need JavaScript enabled to view it.) G. Haesbroeck (This email address is being protected from spambots. You need JavaScript enabled to view it.)